Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma.

Brown MP, Ebert LM, Gargett T.

Clin Transl Immunology. 2019 May 20;8(5):e1050. doi: 10.1002/cti2.1050. eCollection 2019. Review.

2.

Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.

Gargett T, Truong N, Ebert LM, Yu W, Brown MP.

Cytotherapy. 2019 Jun;21(6):593-602. doi: 10.1016/j.jcyt.2019.03.003. Epub 2019 Apr 8.

PMID:
30975603
3.

Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments.

Perrin SL, Samuel MS, Koszyca B, Brown MP, Ebert LM, Oksdath M, Gomez GA.

Biochem Soc Trans. 2019 Apr 30;47(2):625-638. doi: 10.1042/BST20180444. Epub 2019 Mar 22. Review.

PMID:
30902924
4.

Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.

Ebert LM, Yu W, Gargett T, Brown MP.

Biochem Soc Trans. 2018 Apr 17;46(2):391-401. doi: 10.1042/BST20170178. Epub 2018 Mar 14. Review.

PMID:
29540509
5.

Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?

Tan LY, Martini C, Fridlender ZG, Bonder CS, Brown MP, Ebert LM.

Clin Transl Immunology. 2017 Mar 17;6(3):e134. doi: 10.1038/cti.2017.7. eCollection 2017 Mar. Review.

6.

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome.

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, Ruszkiewicz A, Brown MP, Bonder CS, Shackleton M, Ebert LM.

Oncotarget. 2016 Jul 19;7(29):46492-46508. doi: 10.18632/oncotarget.10216.

7.

A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis.

Ebert LM, Tan LY, Johan MZ, Min KK, Cockshell MP, Parham KA, Betterman KL, Szeto P, Boyle S, Silva L, Peng A, Zhang Y, Ruszkiewicz A, Zannettino AC, Gronthos S, Koblar S, Harvey NL, Lopez AF, Shackleton M, Bonder CS.

Angiogenesis. 2016 Oct;19(4):463-86. doi: 10.1007/s10456-016-9520-y. Epub 2016 Jun 23.

8.

Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties.

Moldenhauer LM, Cockshell MP, Frost L, Parham KA, Tvorogov D, Tan LY, Ebert LM, Tooley K, Worthley S, Lopez AF, Bonder CS.

Stem Cell Res. 2015 May;14(3):380-95. doi: 10.1016/j.scr.2015.04.002. Epub 2015 Apr 9.

9.

A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties.

Pitman MR, Powell JA, Coolen C, Moretti PA, Zebol JR, Pham DH, Finnie JW, Don AS, Ebert LM, Bonder CS, Gliddon BL, Pitson SM.

Oncotarget. 2015 Mar 30;6(9):7065-83.

10.

FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.

Tan B, Anaka M, Deb S, Freyer C, Ebert LM, Chueh AC, Al-Obaidi S, Behren A, Jayachandran A, Cebon J, Chen W, Mariadason JM.

Oncotarget. 2014 Jan 15;5(1):264-76.

11.

Fos-icking for control of angiogenesis: increasing the longevity of peritoneal dialysis.

Bonder CS, Ebert LM.

Kidney Int. 2013 Dec;84(6):1065-7. doi: 10.1038/ki.2013.306.

12.

Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J, Behren A, Davis ID, Maraskovsky E, Chen W, Cebon J.

Eur J Immunol. 2013 Feb;43(2):533-9. doi: 10.1002/eji.201242603. Epub 2012 Dec 5.

13.

A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

Ebert LM, MacRaild SE, Zanker D, Davis ID, Cebon J, Chen W.

PLoS One. 2012;7(10):e48424. doi: 10.1371/journal.pone.0048424. Epub 2012 Oct 26.

14.

A novel method for detecting antigen-specific human regulatory T cells.

Ebert LM, MacRaild SE, Davis ID, Cebon J, Chen W.

J Immunol Methods. 2012 Mar 30;377(1-2):56-61. doi: 10.1016/j.jim.2012.01.004. Epub 2012 Jan 13.

PMID:
22265970
15.

Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4.

Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J.

Clin Cancer Res. 2009 Apr 1;15(7):2507-13. doi: 10.1158/1078-0432.CCR-08-2424. Epub 2009 Mar 24.

16.

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.

Nicholaou T, Ebert LM, Davis ID, McArthur GA, Jackson H, Dimopoulos N, Tan B, Maraskovsky E, Miloradovic L, Hopkins W, Pan L, Venhaus R, Hoffman EW, Chen W, Cebon J.

Clin Cancer Res. 2009 Mar 15;15(6):2166-73. doi: 10.1158/1078-0432.CCR-08-2484. Epub 2009 Mar 10.

17.

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.

Ebert LM, Liu YC, Clements CS, Robson NC, Jackson HM, Markby JL, Dimopoulos N, Tan BS, Luescher IF, Davis ID, Rossjohn J, Cebon J, Purcell AW, Chen W.

Cancer Res. 2009 Feb 1;69(3):1046-54. doi: 10.1158/0008-5472.CAN-08-2926. Epub 2009 Jan 27. Erratum in: Cancer Res. 2009 May 15;69(10):4553.

18.

The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.

Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, Kirkpatrick N, Gedye C, Moss D, Ng SP, MacGregor D, Davis ID, Cebon J, Chen W.

Cancer Res. 2008 Apr 15;68(8):3001-9. doi: 10.1158/0008-5472.CAN-07-5664.

19.

Midwifery education and models of care: moving forward mindfully.

Ebert LM.

Women Birth. 2008 Mar;21(1):43-4. doi: 10.1016/j.wombi.2007.11.003. Epub 2008 Feb 1. No abstract available.

PMID:
18243087
20.

Why do women continue to smoke in pregnancy?

Ebert LM, Fahy K.

Women Birth. 2007 Dec;20(4):161-8. Epub 2007 Sep 27. Review.

PMID:
17904432
21.

Comment on "The vast majority of CLA+ T cells are resident in normal skin".

Schaerli P, Ebert LM, Moser B.

J Immunol. 2006 Aug 1;177(3):1375-6; author reply 1376-7. No abstract available.

22.
23.

Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation.

Schaerli P, Willimann K, Ebert LM, Walz A, Moser B.

Immunity. 2005 Sep;23(3):331-42.

24.

Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues.

Ebert LM, Schaerli P, Moser B.

Mol Immunol. 2005 May;42(7):799-809. Epub 2004 Nov 23. Review.

PMID:
15829268
25.

B cells alter the phenotype and function of follicular-homing CXCR5+ T cells.

Ebert LM, Horn MP, Lang AB, Moser B.

Eur J Immunol. 2004 Dec;34(12):3562-71.

26.
27.

Supplemental Content

Loading ...
Support Center